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OBJECTIVES: To compare the ability of four measures of patient retention in HIV 
expert care to predict clinical outcomes and health care utilization over 24 
months. METHODS: This retrospective study examined Veterans Health 
Administration (VHA) beneficiaries with HIV (ICD-9-CM codes 042 or V08) 
receiving expert care (HIV-1 RNA and CD4 tests within 1 week of each other) at 
VHA facilities from October 1, 2006 to September 30, 2008. Patients were 18-89 
years old with ≥24 months of VHA eligibility. Retention measures included: 
“appointments annual” (≥2 appointments annually at least 60 days apart), 
“appointments missed” (missed ≥25% of appointments), “appointments 
infrequent” (≥6 months without an appointment), and “appointments missed or 
infrequent” (missed ≥25% of appointments or ≥6 months without an 
appointment). Outcomes included: virologic suppression (HIV-1 RNA <500), CD4+ 
>500, development of an HIV-related condition, progression to AIDS, emergency 
room (ER) use, and hospitalization. Multivariable regression was used to 
determine associations between retention measures and outcomes. RESULTS: 
Study subjects (n=8,845) had a mean age of 52 years and 97% were male; 51% 
were black, 34% white, 11% other, and 4% unknown. At baseline, 64% of patients 
were virologically suppressed and 37% had a CD4+ >500. At 24 months, 82% were 
virologically suppressed and 46% had a CD4+ >500. During follow-up, 42% 
developed an HIV-related condition, 13.0% progressed to AIDS, 0.3% died, 48% 
visited the ER, and 28% were hospitalized. All four retention measures were 
associated with virologic suppression at 24 months. In addition, “appointments 
annual” was predictive of CD4+ >500 and “appointments missed” was associated 
with CD4+ >500, development of an HIV-related condition, progression to AIDS, 
ER use, and hospitalization. CONCLUSIONS: While all four retention measures 
had clinical value, “appointments missed” was the most accurate predictor of 
clinical outcomes and health care utilization at 24 months among VHA patients 
in HIV expert care.  
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OBJECTIVES: To evaluate clinical and economic burden among Medicare 
beneficiaries hospitalized for acute coronary syndrome (ACS) with comorbid 
atrial fibrillation (AF). METHODS: This study used data from the Medicare 
Current Beneficiary Survey. Patients with an incident hospitalization for ACS 
between March 1, 2002-December 31, 2006 and without similar events during 6 
months prior were included (date of the first event denoted as the index date). 
Comorbid AF was identified from Medicare claims during 6 months prior to the 
index date. Annual health care costs were summarized for the calendar year 
when the incident ACS event occurred. Incidence rates of subsequent 
cardiovascular (CV) hospitalization events and mortality was estimated and 
compared between patients with and without AF. Cox proportional hazards 
regressions were used to estimate the relative risk of AF on mortality and CV-
events adjusting for patient socio-demographic and clinical characteristics. 
Multi-stage sampling design and population weights were accounted for to yield 
national representative estimates. RESULTS: We identified 795 incident ACS 
patients representing over 2.5 million Medicare beneficiaries (mean age 76 years; 
49% male; 13% with AF). Compared with ACS patients who did not have AF, ACS-
AF patients had higher total health care costs ($66,586 vs. $48,031; P<0.001) and 
higher mortality after their ACS admission (574 vs. 277 deaths/1,000 person 
years; P <0.001). Among those discharged alive, patients with AF had a higher 
risk of subsequent CV-events (836 vs. 386 cases; P<0.001) if 1,000 patients were 
followed for 6 months. The adjusted results showed 59% higher risk of CV-events 
associated with AF (HR=1.590; 95% confidence interval: 1.247-2.026). 
CONCLUSIONS: Using a national representative sample of Medicare 
beneficiaries, we observed worse clinical and economic outcomes after 
hospitalization for ACS in patients with comorbid AF. The increased health care 
burden associated with AF underscores the importance of novel strategies to 
address management of this population.  
 
PHS4  
MULTIDISCIPLINARY PHYSICIAN CARE AND MORTALITY IN HEPATOCELLULAR 
CARCINOMA  
Chirikov VV1, Mullins CD1, Hanna NN2, Breunig IM1, Seal B3, Shaya FT1 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland 
School of Medicine, Baltimore, MD, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, 
USA  
OBJECTIVES: Multidisciplinary physician care has increased for many cancers 
yet little evidence exists for hepatocellular carcinoma (HCC). The study objective 
was to evaluate the association between multidisciplinary care and mortality  
in HCC. METHODS: Non-transplant treated patients with an HCC primary 
diagnosis in 2000-07 were followed-up in SEER-Medicare data. Multidisciplinary 
care was operationalized as the number of distinct specialists seen  
pre-treatment, including surgeons, radiology oncologists, intervention 
radiologists, hematologists/medical oncologists, gastroenterologists, and 
generalists. We built survival analysis models controlling for treatment, 
demographics, and clinical characteristics, and adjusted for selection/survival 
bias using inverse probability weighting and time-dependent covariates. 
RESULTS: Of 3320 treated HCC patients, 1323 (40%) saw one, 1250 (38%) saw  
two, and 747 (23%) saw three or more disciplines. Liver directed therapy  
and radiation was administered to a greater proportion of patients  
who encountered multiple specialists compared to those who saw a single 
discipline, who received more resection and chemotherapy. Multidisciplinary 
care was associated with stage 3 HCC and hepatitis C presence. In contrast, 
patients from rural areas and those diagnosed with stage 4 HCC saw fewer 
specialists prior to treatment. In time-dependent, propensity score adjusted 
survival analysis, patients who saw three or more disciplines had 10% (P=0.05) 
reduced mortality, compared to those who saw one discipline. When stratified 
by treatment received, patients on chemotherapy who saw three or more 
disciplines had 28% (P=0.002) reduced mortality. CONCLUSIONS: 
Multidisciplinary care for non-transplant HCC patients was associated with 
reduced mortality, particularly among chemotherapy recipients. While adjusting 
for selection and survival bias, our study may not fully capture the confounding 
effects of referral patterns among specialists on treatment and survival. Our 
findings provide evidence that may further support the development of models 
for coordinated health care delivery such as accountable care organizations 
(ACOs).  
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OBJECTIVES: A pharmacy-based inpatient diabetes management program  
was evaluated to determine if improved glycemic control could be achieved in a 
general medicine patient population. METHODS: A retrospective chart review of 
151 patients with blood glucose (BG) values outside the range 70-180 mg/dL  
was conducted. Observations for the baseline group (n=84) were derived from 
July 2010 and for the intervention group (n=67 ) in October 2010. The odds of  
poor glycemic control for patients in the intervention versus baseline groups 
were assessed by multivariate generalized estimating equations. These methods 
were also used to assess patient characteristics associated with poor glycemic 
control. RESULTS: Across all patients, no evidence was observed indicating  
the pharmacy program decreased the proportion of days spent out of  
the targeted blood glucose range [70-180 mg/dL: OR 0.91 (95% CI: 0.83 – 1.02);  
70-250 mg/dL: OR 1.03 (95% CI: 0.88 – 1.24)]. However, the subgroup of patients 
whose admission blood glucose was less than 200 mg/dL (55% of intervention 
group) experienced a significant reduction in days out of range for both  
ranges [70-180 mg/dL (OR: 0.72, 95% CI: 0.61– 0.88) and 70-250 mg/dL (OR: 0.5, 95% 
CI: 0.33 – 0.71)]. No improvement in glycemic control was observed in patients 
with an admission BG 200 mg/dL or greater. These patients had more disease- 
and social-related factors associated with poor glycemic control. CONCLUSIONS: 
A subpopulation, patients whose admission glucose was less than 200  
mg/dL, experienced improvement in glycemic control in the pharmacy-based 
program. The remaining patients were generally more complicated from  
a disease-state and social perspective and experienced no improvement.  
These patients may require a more intense, multi-disciplinary approach  
that is better matched to the constellation of factors responsible for their 
condition.  
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OBJECTIVES: The WHO with its MPOWER (Monitor Protect Offer Warn Enforce 
Raise) program is assisting the Kingdom of Saudi Arabia (KSA) one of the top 10 
cigarette importing countries with a 29% reported smoking prevalence among 
college Students. This study determined predictors of willingness to quit 
smoking among a cohort of Saudi male college students. METHODS: A cross-
sectional study was conducted in a cohort of male (≥18 years) college students 
that were recruited from three higher education institutions located in two 
regions within KSA. A pre-tested valid survey was used to collect data including 
socio-demographics, addiction level, presence of a smoker within the family, 
social pressure to quit, and number of past attempts to quit. The willingness-to-
quit variable was defined by asking participants if they had seriously thought 
about using smoking cessation strategies. Bivariate and logistic regression 
analyses were performed to assess factors associated with willingness to quit 
smoking. RESULTS: About 467 surveys were received (response rate 51%). 
Around 30% (n=104) of participants were smokers of which 72% (n=75) indicated 
their willingness to quit smoking. The average age of those willingness-to-quit 
was 22.6 (±2.2) years with an income of <$3200/year. The majority (95%) 
attempted to quit at least one time in the past. Only, willingness to quit smoking 
was significantly associated with past quit attempts (P=0.0017; OR=20.6; 
95%CI=3.1-137) after controlling for age, marital status, income, addictive level, 
current or former smoker family member, having a smoker friend, and social 
